OJU1 Stock Overview
Engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Oramed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.05 |
| 52 Week High | US$3.26 |
| 52 Week Low | US$1.89 |
| Beta | 1.77 |
| 11 Month Change | 1.44% |
| 3 Month Change | -5.41% |
| 1 Year Change | 6.43% |
| 33 Year Change | -87.97% |
| 5 Year Change | -38.77% |
| Change since IPO | -78.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| OJU1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -5.0% | -1.3% |
| 1Y | 6.4% | -22.0% | 7.4% |
Return vs Industry: OJU1 exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: OJU1 matched the German Market which returned 7.1% over the past year.
Price Volatility
| OJU1 volatility | |
|---|---|
| OJU1 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OJU1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OJU1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Nadav Kidron | www.oramed.com |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. Fundamentals Summary
| OJU1 fundamental statistics | |
|---|---|
| Market cap | €86.91m |
| Earnings (TTM) | €4.26m |
| Revenue (TTM) | n/a |
20.9x
P/E Ratio0.0x
P/S RatioIs OJU1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OJU1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$4.46m |
| Earnings | US$4.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OJU1 perform over the long term?
See historical performance and comparison